Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.
The increasing popularity of weight loss injections, known as GLP-1 agonists, is prompting a broader discussion about potential side effects beyond their intended benefits. Originally developed for managing type 2 diabetes and obesity, these medications are now being used by individuals even without formal clinical indications, raising concerns among healthcare professionals.
Reports are emerging of some patients experiencing a significant reduction in appetite, a phenomenon informally being termed “agonorexia.” While not yet a recognized medical diagnosis, this condition is characterized by an intense decrease in hunger, potentially leading to substantially reduced food intake. Experts caution that this can carry risks, including significant muscle loss, nutritional deficiencies, persistent weakness, compromised immunity, and metabolic alterations.
The medications in question, such as Ozempic, Wegovy, and Mounjaro, operate by mimicking the effects of the glucagon-like peptide-1 (GLP-1) hormone. According to the World Health Organization (WHO), these drugs “could become an essential tool to combat obesity,” which affects over one billion people globally as of December 1, 2025. However, the potential for unintended consequences, like extreme appetite suppression, is now under scrutiny.
The accelerated weight loss sometimes associated with these medications can be linked to insufficient energy and nutrient consumption. Prolonged restriction increases the risk of malnutrition and functional impairment. GLP-1 agonists act on brain regions related to hunger and satiety, and also slow gastric emptying. Endocrinologist Marina Karam explains that these medications “act in brain regions related to hunger and satiety,” and can also interfere with the brain’s reward system, potentially diminishing cravings not only for food but also for substances like alcohol and tobacco.
Understanding the Mechanism and Potential Risks
The concern surrounding “agonorexia” stems from the powerful impact these drugs have on appetite regulation. As reported by Saúde Abril, the Agência Nacional de Vigilância Sanitária (Anvisa) in Brazil has issued alerts regarding potential health risks associated with the improper use of GLP-1 analogs, including pancreatitis. While the agency’s alert focuses on pancreatitis, the broader issue of unintended side effects, such as appetite suppression, is gaining attention.
The medications’ effect on the reward system, as highlighted by Karam, suggests a more complex interaction than simply reducing hunger. They may diminish the pleasurable associations with food, further contributing to decreased intake. What we have is particularly concerning when the medications are used without medical supervision and proper nutritional guidance.
The Rise of Off-Label Use and Self-Medication
The BBC reported in November 2025 that individuals are increasingly obtaining and using these “skinny pens” without a prescription and outside of clinical guidelines . This self-medication trend is fueling concerns about the potential for adverse effects, as individuals may not be aware of the risks or receive appropriate monitoring.
The WHO emphasized the necessitate for broad access to these medications for those who could benefit from them, but also stressed the importance of responsible use and medical oversight. More than 3.7 million people died in 2024 due to obesity-related diseases, and the organization warns that the number of obese individuals could double by 2030 without effective intervention.
What to Expect Moving Forward
Healthcare professionals are urging individuals considering or currently using GLP-1 agonists to prioritize medical consultation and regular follow-up. The potential for appetite suppression and other side effects underscores the need for careful monitoring and personalized treatment plans. Further research is needed to fully understand the long-term effects of these medications and to develop strategies for mitigating potential risks.
As the use of these medications continues to evolve, ongoing vigilance and open communication between patients and healthcare providers will be crucial. The emerging concerns surrounding “agonorexia” serve as a reminder that even medications with promising benefits can have unintended consequences, and that responsible use is paramount.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance on health-related matters.
What are your thoughts on the increasing use of weight loss medications? Share your perspective in the comments below.